The latest announcement is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical AB has initiated a clinical phase Ib/II study of arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the drug’s efficacy as part of standard 5-FU-based therapy. The trial will assess different dosing regimens to optimize the drug’s effect, marking a significant milestone in Isofol’s efforts to bring arfolitixorin closer to market.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving treatment outcomes for patients with severe cancers. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for solid tumors, including colorectal cancer, which is the third most common cancer worldwide.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.